Cargando…

Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening

BACKGROUND: Glutaric acidemia type 1 (GA1) is a treatable disorder affecting cerebral organic acid metabolism caused by a defective glutaryl-CoA dehydrogenase (GCDH) gene. GA1 diagnosis reports following newborn screening (NBS) are scarce in the Chinese population. This study aimed to assess the acy...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yiming, Wang, Wenjun, Lin, Chunmei, Zheng, Zhenzhu, Fu, Qingliu, Peng, Weilin, Chen, Dongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335863/
https://www.ncbi.nlm.nih.gov/pubmed/34344405
http://dx.doi.org/10.1186/s13023-021-01964-5
_version_ 1783733211008860160
author Lin, Yiming
Wang, Wenjun
Lin, Chunmei
Zheng, Zhenzhu
Fu, Qingliu
Peng, Weilin
Chen, Dongmei
author_facet Lin, Yiming
Wang, Wenjun
Lin, Chunmei
Zheng, Zhenzhu
Fu, Qingliu
Peng, Weilin
Chen, Dongmei
author_sort Lin, Yiming
collection PubMed
description BACKGROUND: Glutaric acidemia type 1 (GA1) is a treatable disorder affecting cerebral organic acid metabolism caused by a defective glutaryl-CoA dehydrogenase (GCDH) gene. GA1 diagnosis reports following newborn screening (NBS) are scarce in the Chinese population. This study aimed to assess the acylcarnitine profiles and genetic characteristics of patients with GA1 identified through NBS. RESULTS: From January 2014 to September 2020, 517,484 newborns were screened by tandem mass spectrometry, 102 newborns with elevated glutarylcarnitine (C5DC) levels were called back. Thirteen patients were diagnosed with GA1, including 11 neonatal GA1 and two maternal GA1 patients. The incidence of GA1 in the Quanzhou region was estimated at 1 in 47,044 newborns. The initial NBS results showed that all but one of the patients had moderate to markedly increased C5DC levels. Notably, one neonatal patient with low free carnitine (C0) level suggest primary carnitine deficiency (PCD) but was ultimately diagnosed as GA1. Nine neonatal GA1 patients underwent urinary organic acid analyses: eight had elevated GA and 3HGA levels, and one was reported to be within the normal range. Ten distinct GCDH variants were identified. Eight were previously reported, and two were newly identified. In silico prediction tools and protein modeling analyses suggested that the newly identified variants were potentially pathogenic. The most common variant was c.1244-2 A>C, which had an allelic frequency of 54.55% (12/22), followed by c.1261G>A (p.Ala421Thr) at 9.09% (2/22). CONCLUSIONS: Neonatal GA1 patients with increased C5DC levels can be identified through NBS. Maternal GA1 patients can also be detected using NBS due to the low C0 levels in their infants. Few neonatal GA1 patients may have atypical acylcarnitine profiles that are easy to miss during NBS; therefore, multigene panel testing should be performed in newborns with low C0 levels. This study indicates that the GCDH variant spectra were heterogeneous in this southern Chinese cohort. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-021-01964-5.
format Online
Article
Text
id pubmed-8335863
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83358632021-08-04 Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening Lin, Yiming Wang, Wenjun Lin, Chunmei Zheng, Zhenzhu Fu, Qingliu Peng, Weilin Chen, Dongmei Orphanet J Rare Dis Research BACKGROUND: Glutaric acidemia type 1 (GA1) is a treatable disorder affecting cerebral organic acid metabolism caused by a defective glutaryl-CoA dehydrogenase (GCDH) gene. GA1 diagnosis reports following newborn screening (NBS) are scarce in the Chinese population. This study aimed to assess the acylcarnitine profiles and genetic characteristics of patients with GA1 identified through NBS. RESULTS: From January 2014 to September 2020, 517,484 newborns were screened by tandem mass spectrometry, 102 newborns with elevated glutarylcarnitine (C5DC) levels were called back. Thirteen patients were diagnosed with GA1, including 11 neonatal GA1 and two maternal GA1 patients. The incidence of GA1 in the Quanzhou region was estimated at 1 in 47,044 newborns. The initial NBS results showed that all but one of the patients had moderate to markedly increased C5DC levels. Notably, one neonatal patient with low free carnitine (C0) level suggest primary carnitine deficiency (PCD) but was ultimately diagnosed as GA1. Nine neonatal GA1 patients underwent urinary organic acid analyses: eight had elevated GA and 3HGA levels, and one was reported to be within the normal range. Ten distinct GCDH variants were identified. Eight were previously reported, and two were newly identified. In silico prediction tools and protein modeling analyses suggested that the newly identified variants were potentially pathogenic. The most common variant was c.1244-2 A>C, which had an allelic frequency of 54.55% (12/22), followed by c.1261G>A (p.Ala421Thr) at 9.09% (2/22). CONCLUSIONS: Neonatal GA1 patients with increased C5DC levels can be identified through NBS. Maternal GA1 patients can also be detected using NBS due to the low C0 levels in their infants. Few neonatal GA1 patients may have atypical acylcarnitine profiles that are easy to miss during NBS; therefore, multigene panel testing should be performed in newborns with low C0 levels. This study indicates that the GCDH variant spectra were heterogeneous in this southern Chinese cohort. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-021-01964-5. BioMed Central 2021-08-03 /pmc/articles/PMC8335863/ /pubmed/34344405 http://dx.doi.org/10.1186/s13023-021-01964-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lin, Yiming
Wang, Wenjun
Lin, Chunmei
Zheng, Zhenzhu
Fu, Qingliu
Peng, Weilin
Chen, Dongmei
Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening
title Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening
title_full Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening
title_fullStr Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening
title_full_unstemmed Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening
title_short Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening
title_sort biochemical and molecular features of chinese patients with glutaric acidemia type 1 detected through newborn screening
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335863/
https://www.ncbi.nlm.nih.gov/pubmed/34344405
http://dx.doi.org/10.1186/s13023-021-01964-5
work_keys_str_mv AT linyiming biochemicalandmolecularfeaturesofchinesepatientswithglutaricacidemiatype1detectedthroughnewbornscreening
AT wangwenjun biochemicalandmolecularfeaturesofchinesepatientswithglutaricacidemiatype1detectedthroughnewbornscreening
AT linchunmei biochemicalandmolecularfeaturesofchinesepatientswithglutaricacidemiatype1detectedthroughnewbornscreening
AT zhengzhenzhu biochemicalandmolecularfeaturesofchinesepatientswithglutaricacidemiatype1detectedthroughnewbornscreening
AT fuqingliu biochemicalandmolecularfeaturesofchinesepatientswithglutaricacidemiatype1detectedthroughnewbornscreening
AT pengweilin biochemicalandmolecularfeaturesofchinesepatientswithglutaricacidemiatype1detectedthroughnewbornscreening
AT chendongmei biochemicalandmolecularfeaturesofchinesepatientswithglutaricacidemiatype1detectedthroughnewbornscreening